Narcolepsy is not associated with increased risk for mortality of any type, even among patients with a higher prevalence of ...

Takeda Pharmaceutical Co.’s experimental narcolepsy drug significantly improved outcome for patients in late-stage clinical trials, and could become the first treatment to target the root cause of the ...

Dr Ahmad Abefe Sanusi is a neurologist at the Al Qunfudah General Hospital in Saudi Arabia. In this interview with SADE OGUNTOLA, he explains why excessive daytime sleepiness and irregular sleep ...

Elaine Chen covers biotech, co-writes The Readout newsletter, and co-hosts STAT’s weekly biotech podcast, The Readout Loud. You can reach Elaine on Signal at elaineywchen.70. Alkermes and Takeda ...

A hormone produced by the brain, orexin, may play a central role in the functioning of the brain’s glymphatic system, which clears waste, according to a new study from the University of Oulu.

Takeda’s orexin receptor 2 agonist oveporexton succeeded in two phase III trials, setting up a first FDA filing for the small molecule for the treatment of narcolepsy type 1. Other companies including ...

Takeda and Alkermes both took data from their orexin receptor 2 (OX2R)-selective agonists to Singapore this morning as the race to get a new class of narcolepsy drugs approved heats up. Takeda ...

Alkermes is also studying its experimental drug alixorexton for narcolepsy and idiopathic hypersomnia, a condition that ...